Geron (GERN) FDA Approvals

Geron logo
$1.00 +0.06 (+6.17%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.00 +0.00 (+0.50%)
As of 11/17/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Geron's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Geron (GERN). Over the past two years, Geron has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as IMpactMF and Imetelstat. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

IMpactMF FDA Regulatory Events

IMpactMF is a drug developed by Geron for the following indication: In patients with relapsed/refractory myelofibrosis (MF). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Imetelstat FDA Regulatory Timeline and Events

Imetelstat is a drug developed by Geron for the following indication: Telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Geron FDA Events - Frequently Asked Questions

In the past two years, Geron (GERN) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Geron (GERN) has reported FDA regulatory activity for the following drugs: Imetelstat and IMpactMF.

The most recent FDA-related event for Geron occurred on October 28, 2026, involving IMpactMF. The update was categorized as "Provided Update," with the company reporting: "Geron Corporation announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decision was based on a recommendation from the independent Data Monitoring Committee (DMC)."

Current therapies from Geron in review with the FDA target conditions such as:

  • Telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies. - Imetelstat
  • In patients with relapsed/refractory myelofibrosis (MF). - IMpactMF
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:GERN last updated on 10/28/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners